SURS Extension Act
Summary
The SURS Extension Act (HR9002) is an early-stage bill that would extend the Quality Payment Program-Small Practice, Underserved, and Rural Support program through fiscal year 2031. It has been referred to two committees and has only one cosponsor, indicating low legislative momentum. No specific funding amount is authorized, and the bill does not directly impact any publicly traded company's revenue stream.
See which stocks are affected
Key takeaways, market implications, full AI analysis, and connected signals are available to HillSignal members.
Already have an account? Log in
Key Takeaways
- 1.Bill is in early legislative stage with low momentum
- 2.No direct financial impact on publicly traded companies
- 3.Program extension does not create new revenue streams for any sector
Market Implications
This bill does not affect any publicly traded company's revenue or competitive position. The program it extends provides technical assistance to small medical practices, not direct procurement or contracts. No market impact is expected.
Full Analysis
On May 21, 2026, Representative Stansbury (D-NM) introduced HR9002, the SURS Extension Act, which would amend the Social Security Act to extend the Quality Payment Program-Small Practice, Underserved, and Rural Support program through fiscal year 2031. The bill was referred to both the Energy and Commerce and Ways and Means Committees. As an early-stage bill with only one cosponsor, it faces a long legislative path. The bill authorizes no specific funding amount; it merely extends an existing program's authorization. Actual funding would require separate appropriations. The program provides technical assistance to small and rural healthcare providers transitioning to value-based payment models under Medicare. No publicly traded companies are directly affected because the program supports provider practices, not product sales. The legislative timeline is uncertain; the bill must pass both committees, the full House, the Senate, and be signed into law. Given the early stage and lack of cosponsors, passage is unlikely in the current session.
Connected Signals
Matched on shared policy language across AI analyses, with ticker & timing weight
Executive Order: Promoting Efficiency, Accountability, and Performance in Federal Contracting
Executive Order: Accelerating Medical Treatments for Serious Mental Illness
ADVANCED TECHNOLOGY INTERNATIONAL: $304M Department of Health and Human Services Contract
Protecting Health Care and Lowering Costs Act of 2025
DELL FEDERAL SYSTEMS L.P: $602M Department of Veterans Affairs Contract
Consolidated Appropriations Act, 2026
OPTUM PUBLIC SECTOR SOLUTIONS, INC.: $1.1B Department of Veterans Affairs Contract
Executive Order: Realigning United States Core Childhood Vaccine Recommendations with Best Practices from Peer, Developed Countries
Related Presidential Actions
Executive orders & memoranda affecting the same sectors or companies
Realigning United States Core Childhood Vaccine Recommendations with Best Practices from Peer, Developed Countries
This executive order directs the CDC and ACIP to review and potentially update the U.S. childhood vaccine schedule to align with recommendations from peer developed countries, which recommend fewer vaccines. It maintains insurance coverage for all currently available vaccines without cost sharing and emphasizes protecting religious liberty and parental authority.
Promoting Efficiency, Accountability, and Performance in Federal Contracting
This executive order mandates that federal agencies default to using fixed-price contracts for procurement, shifting away from cost-reimbursement models. It requires written justification and senior-level approval for any non-fixed-price contract over certain dollar thresholds (e.g., $10M for most agencies, $100M for the Department of War), and directs agencies to review and renegotiate their 10 largest non-fixed-price contracts within 90 days. The order also tasks OMB with implementation guidance and the Federal Acquisition Regulatory Council with proposing regulatory amendments within 120 days.
Accelerating Medical Treatments for Serious Mental Illness
This executive order directs the FDA to prioritize review and facilitate 'Right to Try' access for psychedelic drugs, including ibogaine compounds, that have received Breakthrough Therapy designation for serious mental illnesses. It also allocates $50 million from HHS to support state programs advancing these treatments and mandates collaboration between HHS, FDA, VA, and the private sector to increase clinical trial participation and data sharing for these drugs. The Attorney General is further directed to expedite rescheduling reviews for approved Schedule I psychedelic substances.